NRIX - Nurix Therapeutics  - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

NRIX is currently covered by 11 analysts with an average price target of $25.14. This is a potential upside of $13.67 (119.18%) from yesterday's end of day stock price of $11.47.

Nurix Therapeutics 's activity chart (see below) currently has 61 price targets and 91 ratings on display. The stock rating distribution of NRIX is 94.34% BUY and 5.66% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 40.55% with an average time for these price targets to be met of 192.67 days.

Highest price target for NRIX is $36, Lowest price target is $17, average price target is $28.91.

Most recent stock forecast was given by STEPHEN WILLEY from STIFEL on 09-Apr-2025. First documented stock forecast 18-Aug-2020.

Currently out of the existing stock ratings of NRIX, 50 are a BUY (94.34%), 3 are a HOLD (5.66%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$35

$23.44 (202.77%)

$36

19 days ago
(09-Apr-2025)

2/12 (16.67%)

$25.4 (264.58%)

103

Buy

$27

$15.44 (133.56%)

$28

19 days ago
(09-Apr-2025)

0/23 (0%)

$17.4 (181.25%)

Buy

$25

$13.44 (116.26%)

$20

19 days ago
(09-Apr-2025)

4/5 (80%)

$15.4 (160.42%)

521

Buy

$36

$24.44 (211.42%)

$36

26 days ago
(02-Apr-2025)

2/13 (15.38%)

$24.62 (216.34%)

125

Hold

$17

$5.44 (47.06%)

$10

2 months 25 days ago
(03-Feb-2025)

4/4 (100%)

$-1.95 (-10.29%)

162

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is NRIX (Nurix Therapeutics ) average time for price targets to be met?

On average it took 192.67 days on average for the stock forecasts to be realized with a an average price target met ratio 40.55

Which analyst has the current highest performing score on NRIX (Nurix Therapeutics ) with a proven track record?

DEREK ARCHILA

Which analyst has the most public recommendations on NRIX (Nurix Therapeutics )?

Derek Archila works at WELLS FARGO and has 8 price targets and 5 ratings on NRIX

Which analyst is the currently most bullish on NRIX (Nurix Therapeutics )?

Tyler Van Buren with highest potential upside - $52.14

Which analyst is the currently most reserved on NRIX (Nurix Therapeutics )?

Christopher Liu with lowest potential downside - -$0

Nurix Therapeutics  in the News

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

NX-5948 assigned the nonproprietary name “bexobrutideg” U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemia Achieved $7M in milestones and a $15M license extension fee from ongoing collaboration with Sanofi Enhanced oversight and leadership team with the appointments of Roy D. Baynes to the Board and John Northcott as chief...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?